Authors

Fear of Cancer Recurrence: A Practical Guide for Clinicians

With increasing cancer survival, fear of cancer recurrence (FCR) is becoming a prominent clinical issue. FCR is prevalent, distressing, and long-lasting, and can negatively impact patients’ quality of life, use of health services, and adherence to follow-up recommendations. Novel targeted therapies may increase risk of FCR because of longer treatment duration and follow-up, increased prognostic precision, and omission of treatment based on genomic status.

Primary Central Nervous System Lymphoma-PART 2: Modern Therapeutic Management and Future Directions

In Part 2 of this review article, we discuss the management of primary CNS lymphoma, focusing in particular on systemic therapies and radiation, as well as provide clinicians with a comprehensive overview by covering the key investigations that have brought us to our current state of knowledge, and studies that may guide future interventions.

Management of Triple-Negative Breast Cancer in Older Patients: How Is It Different?

In this review, we will discuss the role of geriatric assessment, alternative treatment modalities for older women with triple-negative breast cancer, and other special considerations for this patient population.

POINT: Chemotherapy vs Abiraterone for the Initial Management of Metastatic Prostate Cancer

Chemotherapy is the best option for the initial management of metastatic prostate cancer.

COUNTERPOINT: Chemotherapy vs Abiraterone for the Initial Management of Metastatic Prostate Cancer

Abiraterone has become the first-choice treatment for men with metastatic prostate cancer.

Immunizing Cancer Patients: Which Patients? Which Vaccines? When to Give?

This article provides guidance to oncology clinicians on vaccine recommendations and safety of use in their patients.

A 35-Year-Old Woman With a Change in HER2 Expression Following Neoadjuvant Chemotherapy for Invasive Breast Cancer

A 35-year-old woman noticed a mass in her right breast and underwent a diagnostic workup, including a mammogram that revealed a 2.4-cm mass and ultrasound that showed two adjacent masses, as well as enlarged axillary lymph nodes.

A 35-Year-Old Woman With a Change in HER2 Expression Following Neoadjuvant Chemotherapy for Invasive Breast Cancer

A 35-year-old woman noticed a mass in her right breast and underwent a diagnostic workup, including a mammogram that revealed a 2.4-cm mass and ultrasound that showed two adjacent masses, as well as enlarged axillary lymph nodes.

Peripheral T-Cell Lymphomas: Incorporating New Developments in Diagnostics, Prognostication, and Treatment Into Clinical Practice-PART 2: ENKTL, EATL, Indolent T-Cell LDP of the GI Tract, ATLL, and Hepatosplenic T-Cell Lymphoma

In Part 2 of this two-part series, this review covers extranodal natural killer/T-cell lymphoma, enteropathy-associated T-cell lymphoma, indolent T-cell lymphoproliferative disorder of the gastrointestinal tract, adult T-cell leukemia/lymphoma, and hepatosplenic T-cell lymphoma.

Identifying Molecular Markers of Relapse in Myelodysplastic Syndrome

In this month's installment of Ask the PI, ONCOLOGY spoke with Meagan A. Jacoby, MD, PhD, and Matthew Walter, MD, about their findings and what they might mean for practicing oncologists.

CheckMate 204: New First-Line Therapy for Asymptomatic Melanoma Brain Metastases?

The results of the phase II trial examining combination immunotherapy were presented during the ASCO 2019 meeting.

Considerations When Initiating Neratinib for Breast Cancer: How to Prevent and Treat Diarrhea

An oncology pharmacist discusses how to prevent and treat diarrhea in patients taking neratinib for breast cancer.

Point: Should Active Surveillance Be Used for Gleason 3+4 Prostate Cancer?

In this Point/Counterpoint, Drs. Bhat and Punnen argue that active surveillance can be beneficial for patients with intermediate-risk prostate cancer.

Point: Should Active Surveillance Be Used for Gleason 3+4 Prostate Cancer?

In this Point/Counterpoint, Drs. Bhat and Punnen argue that active surveillance can be beneficial for patients with intermediate-risk prostate cancer.

Counterpoint: Should Active Surveillance Be Used for Gleason 3+4 Prostate Cancer?

In this Point/Counterpoint, Drs. Madueke and Abern argue that active surveillance should not currently be considered for patients with intermediate-risk prostate cancer.

Breaking New Ground in the Treatment of Advanced Endometrial Cancer

Dr. Makker summarizes the standard of care for the treatment of advanced endometrial cancer, with a look forward to the multitude of clinical trials evaluating novel therapy combinations that are currently enrolling patients or underway.

Suicide in Patients With Cancer: Identifying the Risk Factors

This article reviews the prevalence of suicide in patients with cancer, risk factors, related conditions, and interventions to identify and treat suicidal patients.

Suicide in Patients With Cancer: Identifying the Risk Factors

This article reviews the prevalence of suicide in patients with cancer, risk factors, related conditions, and interventions to identify and treat suicidal patients.

Personality Disorders in Patients with Cancer

Personality disorders become exacerbated under stressful cancer-related situations and may lead to adverse consequences and outcomes.

Suicide in Patients With Cancer: Identifying the Risk Factors

This article reviews the prevalence of suicide in patients with cancer, risk factors, related conditions, and interventions to identify and treat suicidal patients.

Preventing Gastric Cancer Development by Inhibiting the Virulence of H. pylori Infection

Dr. Wilson discusses a chemopreventive drug that may help prevent gastric cancer by acting directly on H. pylori.

Evolving Strategies for the Management of BRAF-Mutant Metastatic Colorectal Cancer

In this article, we review the characteristics of the BRAF mutation and the evolving strategies for managing BRAF-mutant metastatic colorectal cancer.

Brendon M. Stiles, MD, Discusses Low-Dose Radiation Therapy Along with Immunotherapy

The thoracic surgeon from NewYork-Presbyterian Hospital discusses a trial at the institution in which they give low-dose radiation therapy along with immunotherapy at the Annual New York Lung Cancers Symposium®.

Finding the Next Line of Treatment in Melanoma

For those with early-stage melanoma, surgery may be the only treatment needed. However, when melanoma has spread beyond the skin, additional treatments before or after surgery may be necessary.

A 65-Year-Old Man With Back Pain and Imaging Findings of Spinal Cord Compression

Mehmet S. Copur, MD, and colleagues examine the case of a 65-year-old who presented with back pain and a large T8 spinal mass, leading to a diagnosis of multiple myeloma with spinal cord compromise.

A Patient With Newly Diagnosed, Advanced EGFR-Mutated Non–Small Cell Lung Cancer

A 40-year-old woman presented with a productive cough and shortness of breath that limited her regular activities. Her past medical history was relevant for hypertension since 2016; it is well controlled and treated with enalapril 5 mg twice daily. She also revealed a past wood smoke exposure of 2 hours per day for 10 years during her childhood.

Kevin Hughes, MD, on Breast Cancer Treatment Moving Forward

The breast cancer expert spoke about decreasing the amount of treatment to receive the same impact for patients with breast cancer.

The Relationship Between Checkpoint Inhibitors and the Gut Microbiome and Its Application in Prostate Cancer

This review article discusses the concepts of a tumor microenvironment and a gut microbiome and their effects on responses to checkpoint inhibitors (CPIs). It also reviews recent research investigating these 3 topics, and how it can be applied to using CPIs in prostate cancer.

59 Are Choosing Wisely Guidelines Applicable to Patients With a High Ki-67 Proliferation Index and Magee Equation Score?

Future Directions and Collaborations in Multiple Myeloma

Panelists discuss how future directions in multiple myeloma include exciting developments like bispecific T-cell engagers (BiTEs) targeting B-cell maturation antigen (BCMA) and GPRC5D, dual-target chimeric antigen receptor (CAR) T therapies, and revolutionary in vivo CAR T approaches, while emphasizing the importance of nurse education and advocacy, compassionate patient-centered care, and a collaborative community approach where academic centers support community oncologists through accessible communication and shared care, ultimately working toward the goal of curing more patients, as evidenced by one-third of ciltacabtagene autoleucel (cilta-cel) recipients remaining in remission 5 years later without additional therapy.